CTLA4 and neoplasm: He and co-workers also encapsulated DOX, dual ICB antibodies, anti-CTLA-4 and anti-PD-1, into the mPEG-b-PELG hydrogel as a system for tumor immunotherapy and prevention of post-surgical tumor reoccurrence [121].